sales@towardshealthcare.com
+1 804-441-9344
February 2026
The global medical radioactive iodine I-131 market size was estimated at USD 811 million in 2025 and is predicted to increase from USD 862.74 million in 2026 to approximately USD 1505.29 million by 2035, expanding at a CAGR of 6.38% from 2026 to 2035.
The growing health awareness and expanding healthcare are increasing the use of medical radioactive iodine I-131 to tackle the growing thyroid diseases. The companies are also developing new products and are collaborating, which is promoting the market growth.
The medical radioactive iodine I-131 market is driven by growing thyroid disorders and its proven effectiveness in the targeted treatment. The medical radioactive iodine I-131 refers to the radioisotope of iodine, which is used for the diagnosis and treatment of thyroid-related disorders. This radioisotope emits beta and gamma radiation, which helps in the evaluation of thyroid functions, their abnormalities, and monitoring the treatment efficacy.
The use of AI in the medical radioactive iodine I-131 market is increasing, where it is being utilized for the analysis of patient data, which is promoting the development of personalized treatments, combination therapies, and other formulations, with enhanced efficacy and low radiation exposure. It also helps in the detection of various thyroid disorders, where it is also used to identify the disease progress, patient response to the therapy, and dose calculations.
There is a growth in the nuclear medicine facilities globally, where new collaborations are also expanding their services, which is increasing the development of medical radioactive iodine I-131.
The companies are developing various medical radioactive iodine I-131 targeted, personalized, and combination therapies to enhance their efficacy, safety, applications, and reduce their side effects.
Different types of diagnostic and drug delivery systems are being developed, where the companies are also focusing on integrating modern imaging techniques with medical radioactive iodine I-131 to enhance their detection, treatment, and monitoring outcomes.
| Key Elements | Scope |
| Market Size in 2026 | USD 862.74 Million |
| Projected Market Size in 2035 | USD 1505.29 Million |
| CAGR (2026 - 2035) | 6.38% |
| Leading Region | North America |
| Market Segmentation | By Application, By Product, By End User, By Distribution Channel, By Region |
| Top Key Players | Jubilant Draxlmage, NTP Radioisotopes, Curium Pharma, POLATOM, Isotope JSC, Nordion Inc., Cardinal Health |
Why Did the Diagnostic Segment Dominate in the Market in 2025?
The diagnostic segment led the medical radioactive iodine I-131 market in 2025, as they were essential in thyroid cancer detection. They offered enhanced accuracy with lower doses, which increased their use in the various thyroid function tests. Moreover, their non-invasive approach and affordability also increased their acceptance rates.
Therapeutic
The therapeutic segment is expected to show the highest growth during the upcoming years, due to growing thyroid cancer rates. The medical radioactive iodine I-131 also offers enhanced effectiveness, which is increasing its demand. Additionally, increasing health awareness is also increasing their use and innovations.
Which Product Type Segment Held the Dominating Share of the Market in 2025?
The capsule segment held the dominating share in the medical radioactive iodine I-131 market in 2025, due to its longer shelf life. Their easy use and consistent dosing also increased their demand, which enhanced patient compliance. Furthermore, they also offered easy and simple storage and transportation, which increased their adoption rates.
Solution
The solution segment is expected to show rapid growth during the upcoming years, driven by its flexible dosing. The rising paediatric and geriatric population is also increasing its use. Moreover, their personalized dosing and faster absorption rates are also increasing their demand and adoption rates.
How Hospitals Segment Dominated the Market in 2025?
The hospitals segment led the medical radioactive iodine I-131 market in 2025, due to the presence of specialized nuclear medicine departments. At the same time, the presence of radiation safety infrastructure and skilled personnel handling high-dose therapeutic products also attracted the patient. Additionally, advanced diagnostic techniques also increased their dependence.
Clinics
The clinics segment is expected to show the highest growth during the predicted time, due to the growing number of outpatients. This is increasing the use of medical radioactive iodine I-131 for the diagnosis and treatment of various thyroid diseases. They also offer an affordable solution, which is increasing their demand.
Diagnostic Lab
In the clinics segment, the diagnostic lab subsegment is expected to show the fastest growth rate during the forecast period, due to growing health awareness, which is increasing the use of medical radioactive iodine I-131 for thyroid function tests and imaging. Additionally, expanding labs and high patient volumes are also increasing their use.
What Made Hospital Pharmacy the Dominant Segment in the Market in 2025?
The hospital pharmacy segment held the largest share in the medical radioactive iodine I-131 market in 2025, due to the stringent radiation handling and storage facilities. They also offered integration with nuclear medicine and the therapeutic department, which maintained the availability of medical radioactive iodine I-131, increasing their acceptance rates.
Retail Pharmacy
The retail pharmacy segment is expected to show rapid growth during the predicted time, due to growing outpatient volume. The growing demand for low-dose I-131 for diagnostic applications is also increasing its use. Additionally, their widespread availability is also increasing the reliance on them.
North America dominated the medical radioactive iodine I-131 market in 2025, due to the presence of a well-established nuclear medicine infrastructure. The growing thyroid disorders are also increasing their use. Moreover, the advanced healthcare infrastructures and reimbursement policies also increased their use, which contributed to the market growth.
U.S. Market Trends
The U.S. consists of an advanced healthcare infrastructure, which is driving the early adoption of various personalized and targeted medical radioactive iodine I-131 treatment options. The growing thyroid cancer cases and increasing healthcare investments are also increasing their demand and encouraging their advancements.
Asia Pacific is expected to host the fastest-growing medical radioactive iodine I-131 market during the forecast period, due to growing thyroid disorders, which are increasing the use of medical radioactive iodine I-131 for their early and effective diagnosis and treatment. The expanding healthcare and growing awareness are also enhancing the market growth.
China Market Trends
China is experiencing a rise in thyroid disorders, which is increasing the demand for medical radioactive iodine I-131 solutions. The expanding healthcare and growing government initiatives are also increasing their adoption rates, where increasing investments are driving their innovations.
Europe is expected to grow significantly in the medical radioactive iodine I-131 market during the forecast period, due to the presence of advanced healthcare systems, which are increasing the availability of medical radioactive iodine I-131. The stringent regulations, growing innovations, and increased thyroid disease are also promoting the market growth.
The presence of a well-developed nuclear medicine infrastructure and healthcare system is increasing the development and use of medical radioactive iodine I-131. The growing health awareness and government support are also increasing their use for early detection and effective management of thyroid diseases.
| Companies | Headquarters | Medical Radioactive Iodine I-131 Solutions |
| Jubilant Draxlmage | Quebec, Canada | HICON Sodium Iodine I-131 |
| NTP Radioisotopes | Pretoria, South Africa | Fission produced I-131 |
| IRE-IRE ELiT | Fleurus, Belgium | Pharmaceutical-grade I-131 solutions |
| Curium Pharma | London, UK | Sodium iodine I-131 capsules and oral solutions |
| POLATOM | Otwock, Poland | Sodium iodine I-131 capsules and oral solutions |
| Isotope JSC | Moscow, Russia | Bulk I-131 isotopes |
| Lantheus Medical Imaging | Massachusetts, U.S. | Therapeutic I-131 radiopharmceuticals |
| Nordion Inc. | Ontario, Canada | Medical grade I-131 isotopes |
| International Isotopes Inc. | Idaho, U.S. | Sodium iodine I-131 kits |
| Cardinal Health | Ohio, U.S. | Distribution and radiopharmacy services for I-131 |
By Application
By Product
By End User
By Distribution Channel
By Region
February 2026
January 2026
January 2026
January 2026